Nordic Nanovector: Updated results from Phase 1/2 trial of Betalutin® in non-Hodgkin lymphoma to be presented at ASH in December
Oslo, Norway, 1 November 2017 Nordic Nanovector ASA (OSE: NANO) announces that updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with recurrent indolent non-Hodgkin lymphoma (iNHL) will be presented in a poster at the 59th Annual American Society of Hematology (ASH) meeting (9-12 December 2017 in Atlanta, GA, USA). The dataset (as of 3 July 2017) includes 55 evaluable patients. Data from patients receiving the two most promising dosing regimens in the Phase 2 expansion cohorts – Arm 1 (15 MBq/kg Betalutin®